Dextromethorphan-Quinidine for Agitation in Alzheimer Disease
نویسندگان
چکیده
منابع مشابه
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
IMPORTANCE Agitation is common among patients with Alzheimer disease; safe, effective treatments are lacking. OBJECTIVE To assess the efficacy, safety, and tolerability of dextromethorphan hydrobromide-quinidine sulfate for Alzheimer disease-related agitation. DESIGN, SETTING, AND PARTICIPANTS Phase 2 randomized, multicenter, double-blind, placebo-controlled trial using a sequential paralle...
متن کاملThe effect of acute administration of quinidine, dextromethorphan and combination of dextromethorphan/quinidine on pentylenetetrazole-induced clonic and tonic seizure thresholds in mice
Background: Dextromethorphan (DM) as a non-opioid anti-cough has neuroprotective effects. Combination of DM with quinidine decreases rapid metabolism of DM to dextrorphan (DX). This study aimed to examine the effects of acute administration of quinidine, DM and combination of dextromethorphan/quinidine (DM/Q) on pentylenetetrazole (PTZ)-induced clonic and tonic seizure thresholds in mice. Mater...
متن کاملDextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
OBJECTIVE To evaluate dextromethorphan combined with ultra low-dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). METHODS In a 12-week randomized, double-blind trial, ALS and MS patients with clinically significant PBA (a baseline score ≥13 on the Center for Neurologic Studies-Lability Scale [CNS-LS]) we...
متن کاملDonepezil was no better than placebo for agitation in patients with Alzheimer disease.
M e t h o d s Design: Randomized placebo-controlled trial. Allocation: Concealed.* Blinding: Blinded (patients and caregivers, clinicians, outcome assessors, and {data monitoring committee}†).* Follow-up period: 12 weeks. Setting: 8 clinical centers in England, United Kingdom. Patients: 259 patients > 39 years of age (mean age 85 y, 85% women) who had probable or possible Alzheimer disease (on ...
متن کاملP 133: Neuroinflammation in Alzheimer ’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common form of dementia. Almost 47 million people suffer from dementia worldwide. AD accounts for approximately 60%–80% of all dementia cases. Three major pathologies characterize the disease: senile plaques, neurofibrillary tangles and inflammation. We review the literature on events contributing to the inflammat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JAMA
سال: 2016
ISSN: 0098-7484
DOI: 10.1001/jama.2015.18286